论文部分内容阅读
目的:观察接受血运重建的急性冠脉综合征患者住院期间应用他汀类药物对预后的影响。方法:入选本院接受血管重建治疗并且低密度脂蛋白-胆固醇C<100 mg/dL的非ST段抬高急性冠脉综合征患者1121例,根据住院期间是否应用他汀类药物分为他汀组(668例)与非他汀组(453例)。主要不良心脑血管事件定义为死亡、新发心肌梗死、卒中和再次血管重建。结果:他汀组院内不良心血管事件发生率和随访病死率均明显降低(P<0.05,P<0.01),他汀组血管重建后累计病死率(院内及随访死亡)明显低于非他汀组(P<0.01)。经Logistic多因素回归分析,住院期间是否应用他汀类药物与累计病死率显著相关(HR,0.471;95CI,0.245~0.906;P<0.05),并且与随访病死率显著相关(HR,0.328;95CI,0.143~0.753;P<0.01)。结论:住院期间应用他汀类药物可以显著减少急性冠脉综合征患者血管重建术后的住院不良心血管事件,降低累计病死率及随访病死率。
OBJECTIVE: To observe the effect of statins on the prognosis of patients with acute coronary syndrome who underwent revascularization. Methods: A total of 1121 patients with non-ST segment elevation acute coronary syndrome who underwent revascularization and low-density lipoprotein-cholesterol <100 mg / dL were enrolled in this study. Patients were divided into statin group (statin group) 668 cases) and non-statin group (453 cases). The main adverse cardiovascular and cerebrovascular events were defined as death, new myocardial infarction, stroke and revascularization. Results: The incidence of adverse cardiovascular events and the follow-up mortality in the statin group were significantly lower than those in the non-statin group (P <0.05, P <0.01). The cumulative mortality after hospitalization and follow-up in the statin group was significantly lower than that in the non-statin group <0.01). Logistic regression analysis showed that statin use was significantly associated with cumulative mortality (HR, 0.471; 95 CI, 0.245-0.906; P <0.05) during hospitalization and was significantly associated with follow-up mortality (HR, 0.328; 95 CI, 0.143 ~ 0.753; P <0.01). Conclusion: Statin therapy during hospitalization can significantly reduce the adverse cardiovascular events after hospital revascularization in patients with acute coronary syndromes, and reduce the cumulative mortality and follow-up mortality.